A carregar...
Publicação
A critique of the fragility index
Orientador(es)
Resumo(s)
In The Lancet Oncology , Joseph Del Paggio and Ian Tannock report on a retrospective analysis of the fragility indices of phase 3 trials used by the US Food and Drug Administration (FDA) to approve anticancer drugs. 1 The authors conclude that “many phase 3 randomised controlled trials supporting FDA-approved anticancer drugs have a low fragility index, challenging confidence for concluding their superiority over control treatments.” Although this interpretation is interesting, we would like to draw attention to several points.
Descrição
Copyright © 2019 Elsevier B.V. or its licensors or contributors.
Palavras-chave
Contexto Educativo
Citação
Lancet Oncol. 2019 Oct;20(10):e553
Editora
Elsevier